FDA Workshop Tackles Patient Experience in Medicine Making
Published Date: 8/28/2025
Notice
Summary
The FDA is hosting a fun and important workshop to tackle tricky questions about how to collect and use patient experience data when developing new medicines. This event helps patients, drug makers, and doctors work together to make treatments better and more patient-friendly. If you care about medicine that fits real people’s needs, this is your chance to join the conversation and shape the future!
No Economic Impacts Identified for this Document
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2025-16513, Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program; Program Announcement
The FDA is kicking off year four of its Chemistry, Manufacturing, and Controls Development and Readiness Pilot to help drug makers speed up getting important new medicines ready for patients. This program boosts teamwork between the FDA and drug developers, using smart, science-based ways to fast-track drug testing and production. If you’re making a new drug with a fast timeline, now’s the time to apply and get extra support!
Next: 2025-16515, Issuance of Priority Review Voucher; Rare Pediatric Disease Product; MODESYO (dordaviprone)
The FDA just gave a special fast-track ticket called a priority review voucher to Chimerix, Inc. for their rare pediatric disease drug, MODESYO (dordaviprone), approved on August 6, 2025. This voucher helps speed up future drug reviews, benefiting companies working on rare kids' diseases and potentially getting treatments to patients faster. It’s a big win for rare disease drug developers and could impact how quickly new medicines reach the market.